CapsoVision (CV) vs TransMedics Group (TMDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CapsoVision (CV) has outperformed TransMedics Group (TMDX) over the past year, gaining 38.9% versus a loss of 29.6%. TransMedics Group is the larger company by market cap ($2.81 billion vs $348.0 million), about 8.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CV | TMDX |
|---|---|---|
| Share price | $6.54 | $81.07 |
| Market cap | $348.00M | $2.81B |
| 1-day change | +0.62% | +0.98% |
| YTD return | -38.82% | -33.36% |
| 1-year return | +38.85% | -29.61% |
| 5-year return | — | +205.35% |
| P/E ratio (TTM) | — | 20.79 |
| Forward P/E | — | 35.96 |
| EPS (TTM) | $-0.45 | $3.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.37 | $156.00 |
| 52-week low | $4.38 | $60.11 |
| Distance from 52-week high | -57.45% | -48.03% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +23.13% |
| Average volume | 158.95K | 813.21K |
| Shares outstanding | 53.21M | 34.68M |
| Employees | — | 898 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TransMedics Group is about 8.1 times larger than CapsoVision by market value ($2.81B vs $348.00M).
- CV has outperformed TMDX by 68.5 percentage points over the past year.
About TransMedics Group
TMDX stock →TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 898 employees
CV vs TMDX FAQ
Which is bigger, CapsoVision or TransMedics Group?
TransMedics Group (TMDX) is larger, with a market capitalization of $2.81B compared with $348.00M for CapsoVision (CV).
Which stock has performed better over the past year, CV or TMDX?
CV returned +38.85% over the past 12 months, compared with -29.61% for TMDX (price return, excluding dividends). Past performance does not predict future results.
Are CapsoVision and TransMedics Group in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.